Publications dans lesquelles il/elle collabore avec FERNANDO ANTONIO RODRÍGUEZ DE FONSECA (24)

2024

  1. Correction: Plasma concentrations of lysophosphatidic acid and the expression of its receptors in peripheral blood mononuclear cells are altered in patients with cocaine use disorders(Translational Psychiatry, 10.1038/s41398-023-02523-1)

    Translational Psychiatry

2023

  1. Antidepressant Medication Does Not Contribute to the Elevated Circulating Concentrations of Acylethanolamides Found in Substance Use Disorder Patients

    International Journal of Molecular Sciences, Vol. 24, Núm. 19

  2. Antipsychotic Medication Influences the Discriminative Value of Acylethanolamides as Biomarkers of Substance Use Disorder

    International journal of molecular sciences, Vol. 24, Núm. 11

  3. Associations of hypomagnesemia in patients seeking a first treatment of alcohol use disorder

    Drug and Alcohol Dependence, Vol. 245

  4. Plasma Concentrations of Neurofilament Light Chain Protein and Brain-Derived Neurotrophic Factor as Consistent Biomarkers of Cognitive Impairment in Alcohol Use Disorder

    International Journal of Molecular Sciences, Vol. 24, Núm. 2

  5. Plasma Lysophosphatidic Acid Concentrations in Sex Differences and Psychiatric Comorbidity in Patients with Cocaine Use Disorder

    International Journal of Molecular Sciences, Vol. 24, Núm. 21

  6. Plasma concentrations of lysophosphatidic acid and the expression of its receptors in peripheral blood mononuclear cells are altered in patients with cocaine use disorders

    Translational Psychiatry, Vol. 13, Núm. 1

2022

  1. Niveles plasmáticos de midkina en pacientes con trastorno por uso de cocaína en abstinencia

    Adicciones: Revista de socidrogalcohol, Vol. 34, Núm. 4, pp. 273-277

  2. Vascular Endothelial Growth Factor as a Potential Biomarker of Neuroinflammation and Frontal Cognitive Impairment in Patients with Alcohol Use Disorder

    Biomedicines, Vol. 10, Núm. 5

2021

  1. Evaluation of neurotrophic factors and education level as predictors of cognitive decline in alcohol use disorder

    Scientific Reports, Vol. 11, Núm. 1

  2. Trastorno por uso de cocaína y depresión: Cuando el diagnóstico clínico no es suficiente

    Adicciones: Revista de socidrogalcohol, Vol. 33, Núm. 3, pp. 193-200

2020

  1. Cocaine-induced changes in CX3CL1 and inflammatory signaling pathways in the hippocampus: Association with IL1β

    Neuropharmacology, Vol. 162

  2. Plasma tryptophan and kynurenine pathway metabolites in abstinent patients with alcohol use disorder and high prevalence of psychiatric comorbidity

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 102

  3. Potential association of plasma lysophosphatidic acid (LPA) species with cognitive impairment in abstinent alcohol use disorders outpatients

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Inflammatory mediators and dual depression: Potential biomarkers in plasma of primary and substance-induced major depression in cocaine and alcohol use disorders

    PLoS ONE, Vol. 14, Núm. 3

  2. Oleoylethanolamide modulates BDNF-ERK signaling and neurogenesis in the hippocampi of rats exposed to δ9-THC and ethanol binge drinking during adolescence

    Frontiers in Molecular Neuroscience, Vol. 12

  3. Plasma concentrations of oleoylethanolamide in a primary care sample of depressed patients are increased in those treated with selective serotonin reuptake inhibitor-type antidepressants

    Neuropharmacology, Vol. 149, pp. 212-220

  4. Serotonin is the main tryptophan metabolite associated with psychiatric comorbidity in abstinent cocaine-addicted patients

    Scientific Reports, Vol. 9, Núm. 1

2017

  1. Comorbilidad psiquiátrica y valores plasmáticos de 2-acilgliceroles en consumidores de alcohol en tratamiento ambulatorio. Análisis de las diferencias de género

    Adicciones: Revista de socidrogalcohol, Vol. 29, Núm. 2, pp. 83-96

2016

  1. Role of the satiety factor oleoylethanolamide in alcoholism

    Addiction Biology, Vol. 21, Núm. 4, pp. 859-872